Thursday, July 16, 2026·11 stories
Trump stock trades, organ sacks, and gene editing
Today's ethics coverage spans three distinct threads: a sitting president's potential insider trading, a startup's dystopian organ-growing scheme, and the deaf community's exclusion from gene-editing debates. Each raises uncomfortable questions about power, consent, and who gets to decide what's ethical.
